Drug Profile
NEO 6860
Alternative Names: NEO-6860; TRPV1 antagonist - adMare BioInnovationsLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator AstraZeneca Canada
- Developer adMare BioInnovations; NEOMED
- Class Analgesics; Antirheumatics; Benzimidazoles; Small molecules
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Musculoskeletal pain; Neuropathic pain; Visceral pain
Highest Development Phases
- No development reported Musculoskeletal pain; Neuropathic pain; Visceral pain